ChipDX Developing Colon, Breast, Lung, and Tissue-of-Origin Tests for Affymetrix Arrays
December 14, 2010
ChipDX Developing Colon, Breast, Lung, and Tissue-of-Origin Tests for Affymetrix Arrays
The New York-based molecular diagnostics firm is moving ahead with plans to eventually debut at least four microarray-based tests for the clinical market.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Signal Genetics to Buy ChipDx, Gaining Cancer Test Pipeline, Bioinformatics Resources
February 7, 2012 / BioArray News - Affy Files CytoScan with FDA, Plans 'Aggressive' Marketing Campaign to Grow Cyto Business
February 19, 2013 / BioArray News - After 'Pivotal' 2012, Affy Looks to CytoScan, Axiom Genotyping Products to Drive Future Growth
February 5, 2013 / BioArray News - As More Labs Introduce Array-based Prenatal Dx Tests, Debate Rages over Indication, Platform Choice
July 10, 2012 / BioArray News - Affymetrix to Distribute Almac's Xcel Array for Biomarker Discovery
April 3, 2012 / BioArray News